Chuan-Yuan Lin

Dr. Chuan-Yuan Lin

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Clinical and Experimental Dermatology
Verified
Journal Article
Open access
PDF file
SCS. Y. Chen
S. Y. Chen
JLJ. Y. Lin
J. Y. Lin
CLChuan-Yuan Lin
Chuan-Yuan Lin
Injectable poly‐L‐lactic acid (PLLA) was first available in Europe in 1999. It was approved by US FDA for facial filling of lipotrophic HIV patients in 2004 (Sculptra; Dermik Laboratories, Bridgewater, NJ), and then the use of injectable PLLA was further expanded to facial cosmetic applications in 2009. Injectable poly‐D,L‐lactic acid (PDLLA) is a new sub‐dermal filler (AestheFill; REGEN Biotech, Inc., Seoul, South Korea). It was first approved by Korean FDA in 2014. The clinical trials of injectable PDLLA were performed in Korea by Hyun et al. The study was published in Clinical and Experimental Dermatology entitled as “Efficacy and safety of injection with poly‐L‐lactic acid compared with hyaluronic acid for correction of nasolabial fold: a randomized, evaluator‐blinded, comparative study”.

1 May 2020 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
SCSe-Yi Chen
Se-Yi Chen
SCSzu-Ting Chen
Szu-Ting Chen
JLJui-Yu Lin
Jui-Yu Lin
CLChuan-Yuan Lin
Chuan-Yuan Lin
Background: Injectable poly-d,l-lactic acid (PDLLA) is a new collagen-stimulating filler containing PDLLA microspheres and carboxymethyl cellulose. It is available as a lyophilized powder that must be reconstituted with a diluent before administration. The aims of this study were to investigate the efficacy of different diluents and a new accelerating “back-and-forth” method. Methods: Six different diluents, sodium bicarbonate, sterile water for injection (SWFI), normal saline, lidocaine, lidocaine with epinephrine (lidocaine + E), and mannitol, were tested. The recommended “vortex” method for preparation of thin suspensions and a new back-and-forth method suitable for both thin and thick suspensions were compared. Gross and microscopic views of the prepared suspensions were examined. Results: Using the vortex method, only mannitol and SWFI are found to be effective reconstitution diluents for injectable PDLLA. Using the back-and-forth method, all six diluents can be used for reconstitution of injectable PDLLA. Moreover, the time needed for reconstitution of injectable PDLLA by this back-and-forth method is very short, regardless of the thickness of the suspension. Conclusions: Clinically, only SWFI can be used for reconstitution of injectable PDLLA by “hand-shaking” or vortex method. To accelerate the reconstitution time especially when using small amount of SWFI, back-and-forth is the method of choice. Besides, when SWFI is not available, other diluents such as normal saline, lidocaine, or lidocaine + E can be used by this novel back-and-forth reconstitution method.

16 May 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
JLJui‐Yu Lin
Jui‐Yu Lin
CLChuan-Yuan Lin
Chuan-Yuan Lin

25 July 2019 in Plastic and Aesthetic Research
Verified
Journal Article
Open access
CLChuan-Yuan Lin
Chuan-Yuan Lin
JLJui-Yu Lin
Jui-Yu Lin
DYDae-Yeol Yang
Dae-Yeol Yang
SLSeong-Ho Lee
Seong-Ho Lee
JKJeoung-Yong Kim
Jeoung-Yong Kim
MKMiyeon Kang
Miyeon Kang
Plastic and Aesthetic Research is an open acccess journal, which publishes articles on technical and clinical studies related to plastic and aesthetic surgery.

23 August 2024 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
WTWenyun Ting
Wenyun Ting
YCYuming Chong
Yuming Chong
XLXiao Long
Xiao Long
MSMaoguo Shu
Maoguo Shu
HWHaiying Wang
Haiying Wang
XWXiaojun Wang
Xiaojun Wang
Background: Injectable poly-D,L-lactic acid (PDLLA), under the brand name of AestheFill (REGEN Biotech, Inc., Seoul, South Korea), is a biocompatible, biodegradable, and biostimulatory product utilized to correct soft tissue volume loss. Its efficacy and safety have not been fully studied in a large cohort. Objectives: The aim of the study was to evaluate the efficacy and safety of a novel dermal filler injectable, poly-D,L-lactic acid. Methods: This was an evaluator-blinded, multicenter, randomized controlled trial to compare the efficacy and safety of PDLLA vs hyaluronic acid in the correction of the nasolabial fold. Two hundred and sixty patients with moderate to severe nasolabial folds were enrolled and randomized to the treatment group (PDLLA) or control group (hyaluronic acid). Each patient received a PDLLA or hyaluronic acid injection for nasolabial fold augmentation and was followed for 52 weeks. The Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale (GAIS) were applied to evaluate topical nasolabial fold augmentation and overall improvement, respectively. Results: At 24 weeks, 67.6% of patients in the PDLLA group had an at least 1-grade improvement on the WSRS, compared to 60.9% of patients in the control group with an at least 1-grade improvement on the WSRS (P < .05). At each visit, the PDLLA group showed more improvement on the baseline WSRS than the control group. PDLLA was safe and well tolerated, with no severe adverse events. Conclusions: PDLLA shows noninferior efficacy in correcting nasolabial folds compared to hyaluronic acid. Level of Evidence: 2 (Therapeutic):

2 June 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
JLJui‐Yu Lin
Jui‐Yu Lin
NHNai‐Jen Hsu
Nai‐Jen Hsu
CLChuan-Yuan Lin
Chuan-Yuan Lin